B+
Bull case
25%
Probability
Target price
$11.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
PBYI
Puma BiotechnologyBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$8.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+57.8
Score
AI commentary
News tone is mildly positive after the Q2 beat, raised full-year guidance, and approximately 9.5% post-print price increase. Analyst revision and target-change evidence is unavailable, coverage is thin, and social coverage is absent; this supports monitoring rather than a high-conviction upgrade.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Impact
tentative
Confidence
-
AI events
2026-08-08eventQ2 beat and raised full-year outlookMedium impact
Q2 revenue was $56.5M and GAAP EPS was $0.16 versus packet consensus expectations of $53.17M and $0.10. Management raised FY2026 total-revenue guidance to $224–231M and net-income guidance to $17–20M, while lowering royalty guidance. The 8-K furnished the earnings release [#SEC-8K-2026-08-06] [#8-K-2026-08-06].
2026-08-31catalystPost-earnings valuation digestionMedium impact
The shares were quoted at $8.91, up approximately 9.5% from the prior close after the print. With sparse analyst coverage and a reported median target of $6.00, further upside may require continued delivery against raised guidance.
2026-09-30catalystALISCA-Lung2 enrollment initiationHigh impact
Management identified initiation of enrollment in ALISCA-Lung2, a Phase I/II alisertib plus paclitaxel trial in extensive-stage small-cell lung cancer, as a Q3 2026 milestone [#SEC-8K-2026-08-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology